ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients

被引：0
|
作者：
Saam A. Mojtahed
Nicole R. Boyer
Saieesh A. Rao
Thomas F. Gajewski
Jennifer Tseng
Kiran K. Turaga
机构：
[1] University of Chicago,Pritzker School of Medicine, Division of Biological Sciences
[2] University of Chicago,Center for Health and the Social Sciences
[3] University of Chicago,Department of Pathology, Division of Biological Sciences
[4] University of Chicago,Department of Surgery, Division of Biological Sciences
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 576
相关论文
共 50 条
  • [1] ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 576 - 576
  • [2] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Saam A. Mojtahed
    Nicole R. Boyer
    Saieesh A. Rao
    Thomas F. Gajewski
    Jennifer Tseng
    Kiran K. Turaga
    Annals of Surgical Oncology, 2021, 28 : 9039 - 9047
  • [3] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 9039 - 9047
  • [4] Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
    Trouiller, Jean-Baptiste
    Nikolaidis, Georgios F.
    Macabeo, Berengere
    Meyer, Nicolas
    Gerlier, Laetitia
    Schlueter, Max
    Laramee, Philippe
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (04): : 641 - 653
  • [5] Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
    Li, Si Ni
    Wan, Xiaomin
    Peng, Liu Bao
    Li, Ya Min
    Li, Jian He
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [6] Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
    Si Ni Li
    Xiaomin Wan
    Liu Bao Peng
    Ya Min Li
    Jian He Li
    BMC Health Services Research, 23
  • [7] NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
    Presa, M.
    Soria, A.
    Oyaguez, I
    Espinosa, E.
    Echave, M.
    Berrocal, A.
    Manzano, J. L.
    Suarez Rodriguez, J.
    Polanco Sanchez, C.
    VALUE IN HEALTH, 2019, 22 : S457 - S457
  • [8] Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
    Favre-Bulle, Andrea
    Bencina, Goran
    Zhang, Shujing
    Jiang, Ruixuan
    Andritschke, Daniel
    Bhadhuri, Arjun
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 283 - 292
  • [9] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RESECTED STAGE IIB/IIC MELANOMA IN GREECE
    Yfantopoulos, N.
    Spanoudi, F.
    Draganigos, A.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [10] COST PER OUTCOME ANALYSIS OF NIVOLUMAB VERSUS DABRAFENIB plus TRAMETINIB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE IIIB/C BRAF-MUTANT CUTANEOUS MELANOMA IN SPAIN
    Sanchez, Polanco C.
    Moshyk, A.
    Amadi, A.
    Poretta, T.
    Galan, J.
    Vembusubramanian, M.
    Betts, K. A.
    Du, E. X.
    VALUE IN HEALTH, 2020, 23 : S445 - S445
12345